Please try another search
For the nine months ended 30 September 2010, ARYx Therapeutics, Inc. revenues was not reported. Net loss decreased 54% to $12.5M. Lower net loss reflects Research and development decrease of 77% to $4.1M (expense), Interest expense decrease of 21% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.00 to -$0.39.
Period Ending: | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | Dec 31, 2009 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | 0 | |||
Operating Income | -2.15 | -3.24 | -6.02 | -5.31 |
Net Income | -2.51 | -3.64 | -6.39 | -5.79 |
Period Ending: | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | Dec 31, 2009 |
---|---|---|---|---|
Total Assets | 5.97 | 5.02 | 10.57 | 11.97 |
Total Liabilities | 13.71 | 10.95 | 12.98 | 14.89 |
Total Equity | -7.74 | -5.93 | -2.4 | -2.92 |
Period Ending: | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | Dec 31, 2009 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -13.98 | -9.94 | -6.42 | -34.97 |
Cash From Investing Activities | 0.85 | 0.57 | 0.37 | 8.41 |
Cash From Financing Activities | 8.68 | 3.36 | 4.94 | -2.04 |
Net Change in Cash | -4.46 | -6 | -1.11 | -28.59 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review